Can Mandatory Price Transparency Lower Healthcare Costs? What the Data Shows on Hospital Rates, Consumer Shopping, and Market Power

For decades, healthcare economists and reform advocates of all ideological stripes shared a common lament: American healthcare was the only consumer market in the developed world where buyers were legally obligated to purchase multi-thousand-dollar services without knowing the price until weeks or months after delivery ^{[1], [10]}. Hospital chargemasters—the internal, arbitrarily inflated list prices maintained by health systems—bore virtually no relationship to actual operating costs, while the negotiated reimbursement discounts hammered out between commercial insurers and hospital networks were zealously guarded under proprietary trade secret clauses ^{[2], [10]}.

In June 2019, President Donald Trump signed Executive Order 13877, titled 'Improving Price and Quality Transparency in American Healthcare to Put Patients First' ^[11]. The order directed the Department of Health and Human Services (HHS) to enact sweeping federal regulations requiring every acute-care hospital operating in the United States to publish two comprehensive datasets: first, a standardized, machine-readable digital file listing the gross charges, discounted cash prices, and payer-specific negotiated rates for all items and services; and second, a consumer-friendly display of negotiated prices for at least 300 'shoppable' medical services ^{[11], [12]}.

Despite aggressive legal challenges from the American Hospital Association (AHA), the federal courts upheld the mandate in American Hospital Association v. Azar (2020), affirming HHS’s statutory authority under Section 2718(e) of the Public Health Service Act ^[13]. Effective January 1, 2021, and bolstered by the subsequent Transparency in Coverage (TiC) rules requiring commercial health insurers to disclose their negotiated rates, the United States embarked on the world’s largest regulatory experiment in healthcare price disclosure ^{[12], [14]}.

Throughout his political campaigns and ongoing second term, President Trump and conservative policymakers have heralded price transparency as a transformative market triumph that will dismantle hospital price gouging without government price controls or single-payer bureaucracy ^{[1], [11]}. Conservative think tanks, including the America First Policy Institute (AFPI), the Cicero Institute, and the Paragon Health Institute, argue that transparent pricing empowers 250 million privately insured Americans to act as discerning consumers, unleashing competitive pressure that will naturally force high-cost hospital conglomerates to lower their rates ^{[1], [15]}.

To evaluate whether price transparency has fulfilled this promise, The Dispatch conducted an exhaustive investigation into five years of federal compliance audits, peer-reviewed econometric studies, massive commercial claims datasets, and antitrust analyses ^{[2], [3], [7], [9], [16]}. The empirical evidence paints a nuanced, dual-track reality: while consumer shopping has proven to be an economic illusion that leaves national healthcare spending virtually untouched, price disclosure has initiated a quiet revolution in corporate purchasing, employer benefit design, and billing dispute defense ^{[3], [8], [9]}.

What the Data Shows: Do Patients Actually Shop for Healthcare?

The foundational premise of the conservative talking point is consumerism: if prices are made public, patients bearing the financial burden of high deductibles and coinsurance will compare options, select lower-cost providers of equivalent quality, and penalize overpriced hospital systems by taking their business elsewhere ^{[1], [15]}.

However, over a decade of empirical research in health economics has subjected this consumerist hypothesis to rigorous econometric scrutiny—and the findings are overwhelmingly clear: transparent prices do not generate meaningful consumer shopping ^{[3], [4], [5]}.

• The Landmark JAMA Evaluation (Desai et al., 2016): In a pioneering study published in the Journal of the American Medical Association, researchers from Harvard Medical School evaluated two large national employers offering an advanced, web-based price transparency tool to roughly 500,000 employees and dependents ^[3]. Comparing spending trends against a control group without access to the tool, the authors discovered that only 10% of eligible individuals ever logged into the tool during its first year, with usage plunging to under 3% in subsequent years ^[3]. Crucially, access to the tool was associated with zero statistically significant reduction in outpatient spending ^[3].
• High-Deductible Health Plans Fall Short (Mehrotra et al., 2017): Proponents argued that patients in High-Deductible Health Plans (HDHPs) would display far greater shopping diligence because they pay out of pocket before coverage activates ^[1]. Yet research published in Health Affairs tracking tens of thousands of HDHP enrollees found that even when faced with significant out-of-pocket costs, fewer than 12% of patients compared prices before receiving routine imaging or outpatient care ^[5]. Instead of price shopping, patients faced with high deductibles simply reduced their overall utilization across the board, skipping both unnecessary and clinically vital preventive care ^[5].
• The State-Level Public Database Experiment (New Hampshire & Maine): State governments that pioneered mandatory, publicly accessible all-payer price transparency websites (such as NH HealthCost) observed similar patterns ^{[4], [17]}. A comprehensive analysis by Brown University researchers found that while public disclosure led to modest 3% to 5% price reductions for a tiny subset of standardized outpatient diagnostic procedures (primarily standard head and abdominal CT/MRI scans), overall healthcare spending across the state remained entirely unchanged ^{[4], [17]}.

Why Healthcare Defies the Traditional Retail Shopping Model

Why do Americans aggressively compare prices when purchasing automobiles, plane tickets, or electronics, yet fail to shop for medical procedures? Health economists point to four insurmountable structural realities inherent to healthcare delivery ^{[1], [3], [5]}:

First, clinical urgency and non-deferrable demand preclude shopping for a massive share of healthcare expenditures ^[1]. Over 35% of all hospital revenues derive from emergency department admissions, severe trauma, acute cardiac episodes, oncology regimens, and neonatal intensive care—situations where patients lack the physical capacity, time, or cognitive luxury to compare rates across regional hospital networks ^{[1], [2]}.

Second, the insurance benefit architecture creates a 'deductible trap' ^{[3], [18]}. In a standard commercial insurance plan, a patient might face a $3,000 annual deductible and an out-of-pocket maximum of $6,000 ^[18]. When undergoing a $25,000 orthopedic joint replacement or a $40,000 cardiac catheterization, the patient will exhaust their deductible and maximum out-of-pocket liability regardless of whether the hospital charges $18,000 or $38,000 ^{[3], [18]}. Because the insurer pays 100% of the remaining balance, the patient's marginal out-of-pocket cost is zero—completely eliminating any personal financial incentive to select a lower-cost hospital ^{[3], [18]}.

Third, physician referral networks dictate patient choice ^[5]. When a primary care physician orders an MRI, endoscopy, or surgical consult, they routinely write the referral to a specific specialist or hospital department within their own integrated health system ^{[5], [19]}. Patients perceive challenging a trusted doctor's referral as medically risky or socially uncomfortable, viewing the physician's clinical judgment as paramount ^[5].

Finally, there is a pervasive price-quality conflation in medicine ^[5]. Unlike consumer electronics where independent technical benchmarks verify performance, healthcare quality metrics are notoriously opaque to laypersons ^{[1], [5]}. Surveys reveal that many patients instinctively view lower-priced facilities as inferior, substandard, or dangerous—fearing that choosing a $500 independent imaging clinic over a $2,500 academic hospital outpatient department compromises diagnostic accuracy ^[5].

The Compliance Quagmire: Transparency on Paper vs. Usable Reality

Even if consumers possessed the desire and incentive to shop, the practical reality of hospital data disclosure has proven to be an administrative battlefield ^{[12], [16]}. When the Hospital Price Transparency Rule took effect on January 1, 2021, hospital compliance was abysmal ^[16]. Multi-billion-dollar hospital chains openly defied the rule, calculating that the initial federal fine of $300 per day ($109,500 annually) was a trivial cost of doing business compared to the multi-million-dollar competitive advantage of keeping negotiated rates confidential ^{[12], [16]}.

In response to public outcry and bipartisan congressional pressure, CMS substantially overhauled its enforcement framework in 2022 and 2024, implementing a sliding scale of civil monetary penalties reaching up to $5,500 per day (or over $2,007,500 annually) for large hospital systems with more than 550 beds ^[12]. Furthermore, starting in 2024 and finalized in updates effective April 2026, CMS mandated standardized digital schemas, requiring hospitals to publish their Machine-Readable Files (MRFs) using strict, standardized .csv or .json templates that encode exact contracting identifiers, coding systems, and plain-language descriptions ^[12].

Despite these regulatory tightening measures, independent audits demonstrate that true usability remains elusive ^[16]. According to the Eighth Semi-Annual Hospital Price Transparency Compliance Report published in September 2026 by PatientRightsAdvocate.org (PRA), which conducted a comprehensive audit of 2,000 acute-care hospitals across all 50 states ^[16]:

• 49.4% of surveyed hospitals were found fully compliant with all federal disclosure mandates—a marked improvement from 21.1% in late 2024 and a meager 14.3% in 2022, but still leaving more than half of the nation's hospitals deficient ^[16].
• Only 18% of hospitals published clear, dollar-and-cents pricing for at least half of their items and services ^[16]. Instead of explicit dollar amounts, hundreds of hospital files populated data fields with complex algorithms, percentage-of-charge formulas, or uncalculated fee schedules that require specialized actuarial software to decipher ^[16].
• CMS Enforcement Escalation: By mid-2026, CMS had issued formal warning letters to over 500 non-compliant hospitals and levied official civil monetary penalties against 28 hospital systems, with total collected fines exceeding $12 million ^{[12], [16]}.

Simultaneously, the Transparency in Coverage (TiC) rules governing health insurers unleashed an overwhelming torrent of unstructured data ^[14]. Commercial insurers began publishing monthly machine-readable files measuring hundreds of terabytes in size—files so colossal that even major health technology startups struggled to ingest and parse the data without supercomputing infrastructure ^{[14], [20]}. The notion that an ordinary family could browse these files to compare prices before booking an appointment was rendered completely detached from technical reality ^{[16], [20]}.

Antitrust Realities: When Transparency Meets Market Concentration

The core theoretical pillar of free-market economics assumes that in a transparent, competitive market, public price disclosure forces sellers to compete on price, compressing profit margins and driving prices down to marginal cost ^{[6], [7]}. But industrial organization economists and antitrust regulators have long recognized a critical exception: in highly concentrated oligopolies, public price transparency can actually facilitate anti-competitive coordination and drive prices higher ^{[6], [7]}.

This economic phenomenon was famously documented in a seminal study by economists Svend Albæk, Peter Møllgaard, and Per Overgaard published in the Journal of Industrial Economics (1997) ^[21]. When the Danish antitrust authority mandated that ready-mix concrete producers publish firm-specific transaction prices in an effort to spur competition, average concrete prices unexpectedly surged by 15% to 20% within a year ^[21]. Why? Because secret price discounts immediately vanished: suppliers who had previously offered steep private discounts to win customers were forced to eliminate them, while competitors used the public price registry to monitor one another and enforce tacit price collusion without ever holding a secret meeting ^[21].

The Federal Trade Commission (FTC) and the Department of Justice (DOJ) Antitrust Division have repeatedly warned that the American hospital sector is uniquely susceptible to this exact perverse dynamic ^{[6], [7]}. Following three decades of aggressive hospital mergers and acquisitions, more than 90% of U.S. metropolitan healthcare markets are categorized as 'highly concentrated' or 'super-concentrated' under the Herfindahl-Hirschman Index (HHI > 2,500) ^{[6], [19]}. In hundreds of cities, a single hospital conglomerate or a cozy duopoly controls all major acute-care beds and physician networks ^[19].

In a concentrated healthcare market, mandatory price transparency triggers an upward 'ratchet effect' ^{[6], [7]}:

• The Elimination of Concessionary Discounts: Before transparency, a dominant health system might agree to give a regional employer or a budget health maintenance organization (HMO) a 20% confidential discount to secure their patient volume ^[6]. Under universal transparency, the hospital cannot offer that discount without every other major commercial insurer (e.g., Blue Cross, UnitedHealthcare, Aetna) seeing the rate and demanding contractual 'most-favored-nation' parity ^{[6], [7]}. Consequently, hospitals simply terminate concessionary pricing, eliminating the lowest prices in the market ^[6].
• Upward Rate Renegotiation by Lower-Cost Providers: Community hospitals and independent specialty clinics that previously accepted lower reimbursements suddenly gain visibility into the astronomical rates paid to dominant academic medical centers ^[7]. Armed with public machine-readable data during contract renewal cycles, lower-cost providers demand rate hikes: 'We see that you pay System X 350% of Medicare for orthopedics while paying us 210%. Raise our rate to 300% or we terminate our network agreement' ^{[7], [10]}.
• Insurer Resistance Softened by Oligopoly Power: Because commercial health insurers operate on administrative fees or percentage-of-premium margins (and under the ACA’s Medical Loss Ratio rules, must spend 80–85% of premium dollars on clinical claims), insurers facing a hospital monopoly have limited leverage to refuse rate hikes—simply passing higher hospital costs onto employers through higher annual premiums ^{[7], [18]}.

As the FTC noted in an antitrust policy guidance statement, 'Where providers possess substantial market power, transparency regarding payer-specific negotiated rates provides the roadmap for anti-competitive price coordination, removing uncertainty and dampening aggressive competitive bargaining' ^[6].

The Full Picture: Where the Conservative Theory Proves Right

While the data decisively refutes the notion that individual consumer shopping will spontaneously cure healthcare inflation, it would be an analytical error to dismiss price transparency as a policy failure ^{[1], [8], [9]}. Conservative advocates and Trump administration architects were entirely correct on a fundamental strategic insight: opacity in healthcare was an indispensable shield protecting massive corporate arbitrage, price gouging, and predatory billing ^{[1], [10]}. When utilized by institutional buyers and consumer advocates, transparency has generated three undeniable, highly impactful victories ^{[8], [9], [10]}.

1. The Revolution in Self-Insured Employer Contracting and Reference Pricing

In the United States, roughly 160 million Americans receive healthcare coverage through employer-sponsored plans, with approximately 65% of covered workers enrolled in self-insured group plans where the employer—not an insurance carrier—bears direct financial risk for every dollar of medical claims ^[18]. For decades, Third-Party Administrators (TPAs) and health insurers barred employers from seeing their own claims pricing by inserting aggressive 'gag clauses' into administrative contracts ^{[8], [10]}.

Federal transparency rules, combined with statutory gag-clause prohibitions in the Consolidated Appropriations Act (CAA) of 2021, have completely transformed the corporate purchasing landscape ^{[8], [10]}. Forward-thinking employer coalitions—such as the Employers Forum of Indiana and the Peak Health Alliance in Colorado—have leveraged transparent machine-readable files to bypass standard insurer networks and demand revolutionary contracting reforms ^{[2], [8]}:

• Reference-Based Pricing with 'Choice Architecture': While transparency alone fails to induce shopping, peer-reviewed research by Professor James C. Robinson and Christopher Whaley published in Health Affairs proves that transparency paired with reference pricing produces dramatic, sustained cost reductions ^{[8], [9]}. Under reference pricing, an employer establishes a maximum benefit payout for a shoppable procedure (e.g., $30,000 for a total hip replacement or $500 for an MRI), based on transparent regional cost benchmarks ^[8]. If the employee chooses an in-network facility charging at or below the reference price, they pay zero out-of-pocket; if they select a luxury hospital charging $55,000, the employee pays 100% of the $25,000 difference ^{[8], [9]}. Robinson and Whaley documented that reference pricing shifted 70% of surgical and imaging volume to high-value, lower-cost facilities within two years, slashing procedure spending by 14% to 20% without any decline in clinical outcomes ^{[8], [9]}.
• Direct Contracting and Bundled Surgery Centers: Armed with transparent data exposing that university medical centers were billing $45,000 for outpatient orthopedic surgeries, employers have directly contracted with ambulatory surgery centers (ASCs) and specialty surgical suites to perform joint replacements and spinal fusions for all-inclusive bundled rates of $15,000 to $18,000—sharing the savings directly with employees through zero copays and cash bonuses ^{[8], [10]}.

2. Shielding the Uninsured and Defeating Predatory Medical Debt

Perhaps the most immediate, tangible benefit of federal price transparency has accrued to the roughly 26 million uninsured Americans and patients facing out-of-network balance bills ^{[10], [16]}. Historically, when an uninsured patient walked into an emergency department or underwent emergency surgery, hospitals billed them at 100% of the mythical 'chargemaster' rate—frequently 400% to 1,000% higher than the actual reimbursement accepted from commercial insurers or Medicare ^{[10], [20]}.

Under 45 CFR § 180.50, hospitals are legally mandated to publish their established discounted cash prices alongside negotiated rates ^[12]. In thousands of documented cases, patient advocacy organizations, legal aid clinics, and medical billing negotiators have weaponized this data to dismantle predatory collections ^{[10], [16]}. When a hospital bills an uninsured patient $12,000 for an appendectomy or $3,500 for a CT scan, patient advocates pull the hospital’s own mandatory machine-readable file to prove that the facility’s published discounted cash price is $2,800 and its median commercial negotiated rate is $2,100 ^{[10], [16]}. In small-claims courts and debt collections across the country, judges have repeatedly struck down predatory hospital debt claims, ruling that a hospital cannot legally enforce chargemaster rates when its own public filings establish an objective cash-pay market standard ^[10].

3. Exposing Hospital Outpatient Department (HOPD) Arbitrage and Driving Site-Neutral Reform

Price transparency has provided indisputable empirical ammunition to expose one of the largest drivers of healthcare inflation: hospital-physician consolidation and site-based billing arbitrage ^{[2], [19]}. Over the past decade, major health systems acquired thousands of independent physician practices, converting standard doctor's offices into 'Hospital Outpatient Departments' (HOPDs) ^[19]. By tacking on a separate, predatory 'facility fee' to standard office visits, colonoscopies, and chemotherapy infusions, hospitals legally doubled or tripled their bills for the exact same clinical service performed in the exact same examination room ^{[19], [22]}.

Public machine-readable data finally laid this arbitrage bare for the public and lawmakers to see ^{[2], [22]}. For example, transparent datasets revealed that a 15-minute heart echocardiogram billed at $350 in an independent cardiologist's office surged to over $1,800 once the practice was acquired by a hospital conglomerate ^{[2], [22]}. This unprecedented transparency has unified conservative fiscal hawks, progressive reformers, and the Medicare Payment Advisory Commission (MedPAC) behind sweeping 'site-neutral payment' legislation in Congress, with the Congressional Budget Office (CBO) estimating that equalizing Medicare payments across clinical settings would save federal taxpayers over $140 billion over a decade ^[22].

Conclusion

The national debate surrounding healthcare price transparency illustrates the critical difference between retail market theory and the complex realities of modern medical delivery ^{[1], [3], [8]}. The conservative talking point championed by Donald Trump and free-market advocates—that publishing prices will turn ordinary patients into aggressive bargain shoppers who discipline hospital conglomerates—is fundamentally contradicted by empirical data ^{[3], [4], [5]}. A decade of peer-reviewed research confirms that clinical urgency, complex insurance benefit designs, physician referral locks, and opaque quality indicators prevent patients from behaving like retail consumers ^{[3], [5]}. When patients are facing severe health crises, shopping is neither practical nor humane ^{[1], [3]}.

Furthermore, in the 90% of American cities where hospital monopolies reign supreme, public price transparency unaccompanied by antitrust enforcement carries genuine economic perils ^{[6], [7]}. By removing private price uncertainty, transparency can facilitate tacit collusion, prompting lower-cost community providers to ratchet their rates upward toward the dominant system’s price ceiling ^{[6], [7], [21]}.

Yet rejecting the conservative premise entirely would ignore the most significant tool introduced to American healthcare finance in a generation ^{[8], [10]}. Price transparency was never truly capable of turning individual patients into price fighters; rather, its true revolutionary power lies in arming institutional buyers and equalizing information asymmetry ^{[8], [10]}. For self-insured employers representing 160 million workers, transparent data has unlocked reference pricing, direct contracting, and centers of excellence that yield verified 14% to 20% spending cuts ^{[8], [9]}. For the uninsured, it has established an enforceable shield against usurious medical debt ^[10]. And for federal policymakers, it has exposed the absurdities of facility fee markups, creating unstoppable momentum for site-neutral payment parity ^[22].

Mandatory price transparency is not a panacea that can single-handedly rescue the American healthcare economy from monopolistic consolidation ^{[1], [6]}. But as a foundational baseline of accountability, it is indispensable ^[10]. To realize its true potential, transparency must not be treated as an end in itself, but as the raw intelligence that fuels aggressive antitrust enforcement, site-neutral payment reform, and innovative employer benefit architecture across the nation ^{[6], [8], [22]}.